NMIN

EVENTS

Capacity-building Webinars

Ongoing 

NMIN

NMIN 2020 Workshop Series

Designing Effective Commercialization Plans for Grant Proposals

A series of online NMIN Capacity-Building workshops

PLEASE NOTE: Registration for this workshop series is restricted to NMIN participants (investigators, collaborators, HQP and committee members).

This workshop series has been designed specifically for NMIN investigators, collaborators, HQP, and Committee members to improve their ability to address commercially relevant evaluation criteria such as market size in their research planning and grant proposal writing, and to hone their skills in conducting competitive analysis. It will also enable participants to understand how to design studies with endpoints relevant to potential commercial partners.

The series includes four experiential workshop sessions offered over a period of seven weeks.

Participants will have the opportunity to develop and receive feedback on their own research proposals and/or grant applications. This workshop aims to optimize their skills in project design, grant writing, and attracting industry collaboration and investment. For NMIN PIs in particular, the workshop learnings will increase their chances for securing and leveraging additional resources for current NMIN projects as well as future NMIN calls for research proposals.

These workshops will provide participants with the skills to:

  • convincingly demonstrate the commercialization potential of their research;
  • clearly communicate market opportunities;
  • identify clinically relevant treatment goals; and
  • design pre-clinical experiments that will de-risk development and attract commercial partners.

In addition to leading the workshop sessions, Christine Charette will be available to registrants for one-on-one consultations on a first-come, first-serve basis.

Christine Charette, Scientia Advisors Inc.

Christine Charette is an accomplished life sciences executive with over 25 years of investment, advisory, business development, capital markets, strategic planning and analysis, and marketing experience. She is an expert in translating scientific data into market potential and company strategy.     

As Managing Partner and Founder of Scientia Advisors and Investments, she advised and facilitated fund raising for emerging life sciences companies. She founded the life science group at BMO Capital Markets, where she was the Managing Director of the Biotech/Pharmaceutical research group for 16 years, helping raise over $3 billion for life science companies.

She is multiple award winner, and was awarded the rare designation of “super-analyst” in recognition of her high regard by both investors and life science company management.

Christine is a founding member of NMIN’s Board of Directors and is the designated Board Observer on the NMIN Research Management Committee.

Resources from these workshops (video recordings, the presenter’s slides, reading material) are available to NMIN participants only.

For a password to access these resources, please contact leahgraystone@nanomedicines.ca.

Session 1

DEVELOPING A TARGET PRODUCT PROFILE (TPP)

Wednesday, October 21, 2020, 4:00 pm ET

60-minute workshop, 30-minute discussion (optional)

Following this workshop, participants will have the resources and tools needed to assess current and potential future standard of care and determine the attributes needed for a new product to be competitive within that context. Following the workshop, participants will be able to design a commercially relevant TPP.

A recording of this workshop is available. For access, please contact leahgraystone@nanomedicines.ca.

Session 2

DESIGNING A PROOF OF CONCEPT (POC) STUDY

Tuesday, November 3, 2020, 4:00 pm ET

60-minute workshop, 30-minute discussion (optional)

Participants will learn how to use the TPP discussed in the first workshop to “work backwards” and determine what POC experiment will be needed to convince potential commercial partners that their new product will be competitive. They will learn the elements needed to design an appropriate go/no go experiment based on elements of a TPP and what data is needed to validate an idea.

A recording of this workshop is available. For access, please contact leahgraystone@nanomedicines.ca.

Session 3

ASSESSING MARKET SIZE

Tuesday, November 24, 2020, 4:00 pm ET

60-minute workshop, 30-minute discussion (optional)

The lung cancer market may be a $10 billion market, but a new product will not necessarily achieve those sales levels. Credibility with potential investors will go a long way if your market assessment is reasonable and you have a well-articulated value proposition. This workshop will provide participants with resources and help them to critically assess achievable potential sales based on the TPP and competitive positioning.

A recording of this workshop is available. For access, please contact leahgraystone@nanomedicines.ca.

Session 4

ASSESSING PARTICIPANT PROJECTS AND Q&A

Tuesday, December 8, 2020, 4:00 pm ET

60-minute workshop, 30-minute discussion (optional)

The final session will involve participants assessing written projects presented by fellow investigators following the three previous workshops with input from Scientia Advisors, followed by a Q&A “ask me anything” session. This workshop will provide participants with an opportunity to bring learnings from across the series together and improve their ability to articulate the commercial relevance of their projects.

Registration is complementary but required.
Registration for this workshop series is restricted to NMIN participants (investigators, collaborators, HQP and committee members).

NMIN

Check back soon

More webinars are being planned…

NMIN

PAST WEBINARS

NMIN

rhAmpSeq™ CRISPR: Multiplexed Amplicon Sequencing & Analysis

NMIN Capacity-building Webinar

Monday, November 16, 2020

1:00 – 2:00 pm (PST) | 4:00 – 5:00 pm (EST)

Resources are available for this webinar:

Slides | Video

Note: The slides are provided as a PDF with links from each slide to the corresponding section of the video recording.

CRISPR-Cas9 allows for the rapid and specific editing of genomic DNA but sequencing and quantifying those edits can be challenging and time consuming. There is also a risk of off-target editing that can have undefined consequences. Utilizing robust guide design tools, delivering ribonucleoprotein (RNP) complexes instead of plasmids and the use of high fidelity Cas9 enzymes can reduce this risk it is still important to check for off-target edits.

In this seminar, organized with Integrated DNA Technologies (IDT), Dr. Adam Chernick presented rhAmpSeq™ for CRISPR as a tool for generating NGS-ready libraries targeting both on- and off-target sites in a genome. This tool can be coupled to an upcoming analysis pipeline to robustly analyze the resulting NGS data to determine the sequence and frequency of edits at these sites.

Watch the recording below to learn more about best practices for characterizing on- and off-target editing in your CRISPR experiments.

Adam Chernick, Integrated DNA Technologies (IDT)

Adam Chernick completed his Bachelor of Health Sciences in Biomedical Sciences and his PhD in Veterinary Medical Sciences at the University of Calgary, Canada. His doctoral research focused on the evolution of ssRNA viruses infecting cattle and relied heavily on basic molecular biology techniques as well as more novel methods including next generation sequencing.

He started at IDT as an Inside Sales Representative and Business Analyst for Canada. Today, he is a Field Application Manager at IDT for functional genomics products including CRISPR, covering the Western US and Western Canada.

NMIN

Mitacs Internship & Fellowship Opportunities

An NMIN Capacity-Building HQP webinar

Wednesday, October 14, 2020

1:30 – 2:30 pm (EDT) | 10:30 – 11:30 am (PDT)

Resources are available for this webinar:

Slides | Video

Note: The slides are provided as a PDF with links from each slide to the corresponding section of the video recording.

NMIN-Mitacs Internships enable an internship opportunity for NMIN HQP who wish to work with non-academic partner organizations on research projects that involve nanomedicine. Through partnership with Mitacs, 430 internship units (valued at approximately $6.5 Million) have been made available for NMIN HQP.

In the Mitacs Internship and Fellowship Opportunities webinar, Dr. Sherry Zhao discussed to the Mitacs Accelerate Program and the Mitacs Elevate Postdoctoral Fellowship program, and how NMIN HQP can access and benefit from these opportunities.

The Mitacs Accelerate Program provides paid internships for graduate students and trainees at industry partner organizations. This program supports trainees and graduate students to apply their skills in non-academic environments, broaden professional networks, and build their CVs.

Mitacs Elevate is a postdoctoral fellowship with a customized research management training component. Elevate fellows progress through the program in a cohort, giving them cross-disciplinary networking and peer-learning opportunities they might not otherwise have access to in their careers.

Sherry Zhao, Mitacs

Dr. Sherry Zhao, PhD, joined the Mitacs Business Development team in 2014. As the Senior Account Manager, she works with major industry partners to support their innovation pipeline.

A first-generation immigrant, she believes in the power of diversity and globalization. She serves on the UBC China Council, & as a steering committee member for NEXT leaders initiative at Business Council of British Columbia. She also has a strong passion for lifestyle wellness, particularly in educating and empowering women in such endeavors.

Dr. Zhao previously worked at Genentech, a member of Roche, supporting the technology development for biopharmaceutical characterizations. She also led the largest site in Canada for Let’s Talk Science, a national STEM outreach organization, as the Executive Coordinator

NMIN

Navigating Intellectual Property (IP) Risk

An NMIN Capacity-Building HQP webinar

Thursday, June 25, 2020

3:00 – 4:30 pm (EST) | 12:00 – 1:30 pm (PST)

Resources are available for this webinar:

Slides | Video

Note: The slides are provided as a PDF with links from each slide to the corresponding section of the video recording.

Have a great idea for a life sciences start-up?

Have you checked if there are any blocking patents?  Have you checked to see if someone already has rights to your planned brand?

If your answer is “no,” you are not alone.  In fact, few scientists launching life sciences start-ups have the knowledge or the tools to effectively manage and navigate intellectual property (IP) risk.  Rarely are these skills taught as part of university science curricula. 

In this webinar, patent/IP and trademark experts Wendy Lamson and Coleen Morrison distilled this topic down to an easy-to-understand synthesis and provided practical tips and tricks on how to manage IP risk throughout product development to mitigate future infringement. 

Participants left the webinar equipped with practical solutions that they can implement in their organizations now, or in future start-ups.

Wendy Lamson is Partner and Patent Agent at Perley-Robertson, Hill & McDougall. She has over 20 years of experience drafting and prosecuting patent applications. Most of her career has been devoted to developing broad and defendable patent portfolios for her clients. Wendy successfully developed and defended a patent portfolio for a 300-employee Ottawa-based biotech company, growing their portfolio from less than 10 patent applications to over 300 patent applications world-wide. Earlier in her career, she was instrumental in developing a patent portfolio directed to lipid-based formulations for Celator Pharmaceuticals, a biotech company now owned by Jazz Pharmaceuticals. She now counsels start-ups and mid-size companies on best practices for optimizing protection of their intellectual property and reducing their IP risk exposure.

Coleen Morrison is Partner, Barrister & Solicitor Trademark Attorney, at Perley-Robertson, Hill & McDougall. She has over 20 years of experience representing clients spanning all areas of trademark practice, along with other areas of IP such as copyright, industrial designs and domain names.

Coleen has filed and prosecuted more than 5000 trademark applications in Canada and has been involved in well over 1000 trademark Oppositions. She also has extensive experience providing strategic advice to Canadian small and medium enterprises wishing to protect their IP in Canada and around the world.

Coleen is the current President of the Canadian Association of the International Federation of Intellectual Property Attorneys (FICPI) and the President of FICPI’s Work and Study Commission (CET). She is a fellow of the Intellectual Property Institute of Canada and vice-Chair of this organization’s Trademark group.

Registration to this event is free, but required. Upon registering, you will receive information by email about how to join the webinar. This event is intended mainly to benefit members of NMIN’s HQP program, but all are welcome.

NMIN

Developing an Entrepreneurial Mindset

An NMIN Capacity-Building HQP webinar

Tuesday, February 18, 2020

2:00 – 3:00 pm (EST)

Resources are available for this webinar:

Video

This webinar is designed to introduce STEM graduate students, post-doctoral fellows and faculty to some of the frameworks and skills required to commercialize their inventions.

Dr. Elicia Maine, a specialist in technological innovation and science entrepreneurship, will discuss the challenges involved in pursuing science-based business ventures and translating university inventions into innovation. 

Dr. Maine will outline three potential paths by which to take breakthrough inventions from lab to market, and offer insights into the entrepreneurial capabilities that can be employed before a science-based venture is even founded to enhance the likelihood of success.

The event will also provide an introduction to the Invention to Innovation (i2I) entrepreneurship program, a program at Simon Fraser University that helps scientists and engineers commercialize their inventions and overcome marketplace challenges. In a panel discussion, i2I alumni will discuss the value they derived from the program and their experiences in applying these learnings to the real world of scientific entrepreneurialism.


Elicia Maine is the W.J. VanDusen Professor of Innovation & Entrepreneurship at the Beedie School of Business at Simon Fraser University, where she teaches  “Managing Technological Innovation” and “Lab to Market.”  She is also Academic Director of SFU’s Invention to Innovation (i2I) Program. Her research interests are in technological innovation and science & technology entrepreneurship.

Dr. Maine was the founding educational coordinator for New Ventures BC, was awarded the 2017 TD/Canada Trust Distinguished Teaching Award, and was recognized as one of BC’s Most Influential Women 2018: STEM Stars. She serves on the Boards of Directors of the Foresight Cleantech Accelerator, the Composites Knowledge Network and Innovate BC’s New Ventures BC, and is actively involved in innovation initiatives and in mentoring scientist-entrepreneurs.

An interdisciplinary scholar and engaged educator, she holds a PhD in Technology Management & Materials Engineering from the University of Cambridge, Master’s degrees in Technology & Policy and Materials Engineering from the Massachusetts Institute of Technology, and a BSc in Materials Engineering from Queen’s University. Dr. Maine has published her innovation management research in Research Policy, R&D Management, Research-Technology Management, Technovation, Journal of Engineering and Technology Management, Nature Nanotechnology and Nature Materials

Invention to Innovation (i2I) Alumni Panel

Jayesh Kulkarni, PhD.

Scientist, Evonik

Jayesh “Jay" Kulkarni is currently a Scientist at Evonik Canada Inc. focused on the development of lipid nanoparticles for gene therapy. He completed his PhD in Biochemistry and Molecular Biology from UBC in 2018 under the supervision of Dr. Pieter Cullis; his work focused on the characterization of lipid nanoparticle formulations of nucleic acid. Jay was part of the 2018 cohort of students in the i2I program which helped him convert a basic scientific finding into an innovative approach to enabling nucleic acid delivery. He has co-founded a company developing gene editing therapeutics for neurological diseases.

Ada Leung, PhD.

Director of Operations & Co-Founder, Cuprous Pharmaceuticals Inc.

Dr. Ada Leung completed her PhD at the University of British Columbia (BC Cancer) where she focused on identifying novel genes and proteins that could be targeted to improve chemotherapy treatment outcomes for lung cancer. During her PhD, Dr. Leung undertook a side project which contributed to the development of the Metaplex technology and the founding of Cuprous Pharmaceuticals. As a scientist-entrepreneur, Dr. Leung manages Cuprous’ research programs and business operations and actively participates in entrepreneurship training through UBC Hatch and SFU Beedie School of Business. She recently enrolled in the first online cohort of the SFU/Mitacs joint Invention to Innovation (i2I) program.

Bahar Motlagh, PhD.

Manager, Device Development Lab (DDL), Sunnybrook Health Sciences Centre

Bahar Motlagh has a PhD in Biomedical Engineering from Polytechnique Montreal with focus on design and fabrication of micro/nano size medical devices. She worked as an entrepreneur/ project leader in TandemLaunch Inc. in Montreal before taking part in the i2I program at SFU. She was the First Place Finisher in the emergent/social venture category in the 2017 Venture Pitch Competition at SFU Beedie School of Business. She is now working in Sunnybrook Health Sciences Centre as a manager of Device Development Lab(DDL).

Registration to this event is free, but required. Upon registering, you will receive information by email about how to join the webinar. This event is intended mainly to benefit members of NMIN’s HQP program, but all are welcome.

Questions: contact Leah Graystone, NMIN Events & HQP Program Coordinator, at: leahgraystone@nanomedicines.ca